trending Market Intelligence /marketintelligence/en/news-insights/trending/qqpnxhtk7_owedk5v1cdwq2 content esgSubNav
In This List

Noxopharm raises A$10.8M from share placement for front-line drug

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Noxopharm raises A$10.8M from share placement for front-line drug

Australia's Noxopharm Ltd. raised A$10.8 million to accelerate the clinical development of its cancer drug NOX66.

Under the share placement, the drug development company offered 12 million fully paid ordinary shares, priced 90 cents apiece, to sophisticated and institutional investors.

Settlement of 7,264,966 of the placement shares is expected to occur March 29. Issuance of the 4,735,034 remaining shares will be subject to shareholder approval.

Bell Potter Securities Ltd. was the lead manager and book runner for the placement, with APP Securities as co-manager.

NOX66 is a dosage formulation of experimental anti-cancer drug idronoxil.